LEGACY STUDY SEARCH RESULTS

72 studies found for your search request:  Schering-Plough/Organon studies

ALOXI (palonosetron) (MK-4291-001)
Condition: Nausea, Chemotherapy-induced
ClinicalTrials.gov Identifier: NCT00687011 (view full study on clinicaltrials.gov)
Phase: Phase IV
Company: Schering-Plough

ALOXI (palonosetron) (MK-4291-002)
Condition: Nausea, Chemotherapy-induced
ClinicalTrials.gov Identifier: NCT00684463 (view full study on clinicaltrials.gov)
Phase: Phase IV
Company: Schering-Plough

CLARINEX (desloratadine) (MK-7079-001)
Condition: Rhinitis, Seasonal Allergic
Phase: Phase II
Company: Schering-Plough

CLARINEX (desloratadine) (P02879)
Condition: Chronic Idiopathic Urticaria
Phase: Phase IV
Company: Schering-Plough

CLARINEX (desloratadine) (P02904)
Condition: Rhinitis, Seasonal Allergic
Phase: Phase III
Company: Schering-Plough




Copyright © 2022 · Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site